FDA clears Medtronic’s Hugo robotic system for general surgery procedures
The U.S. Food and Drug Administration granted clearance for Medtronic’s Hugo™ robotic‑assisted surgery system to be used in a range of upper and lower abdominal general surgery procedures, including cholecystectomy, gastric bypass, ventral hernia, inguinal hernia and appendectomy. The cleared procedures represent roughly 3.5 million surgeries performed annually in the United States. Medtronic said the expansion positions Hugo to exceed 50,000 global procedures by the end of its fiscal year.
Why it matters
The company expects the broader indication to drive higher procedure volumes and accelerate adoption in U.S. hospitals, which could boost revenue from the Hugo platform (the company states it aims to surpass 50,000 procedures by fiscal‑year end).
Key facts
- 1The FDA clearance was announced on 17 Nov 2026. prnewswire.com
- 2The clearance covers all upper abdominal general surgical procedures and two lower abdominal procedures, accounting for about 3.5 million annual U.S. surgeries. prnewswire.com
- 3Medtronic projects the Hugo system will exceed 50,000 procedures globally by the end of its fiscal year. prnewswire.com
- 4Medtronic’s senior vice president and president of Surgical business, Matt Anderson, said the clearance expands choice and flexibility for hospitals. prnewswire.com
Open questions
- Stock price reported as $102.88 and $102.85 in pre‑market trading.
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.